Phase 2
N=31
NNITS-Nitazoxanide for Norovirus in Transplant Patients Study
Gastroenteritis Norovirus
Bottom Line
View on ClinicalTrials.gov: NCT03395405 ↗Enrolled (actual)
31
Serious AEs
6.5%
Results posted
Oct 2022
Primary outcome: Primary: Time to Initial Clinical Resolution of Norovirus Symptoms — 19; 11 days — p=0.459
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Nitazoxanide (Drug); Placebo (Other)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Initial Clinical Resolution of Norovirus Symptoms |
19; 11 | 0.459 |
| SECONDARY Number of Participants Experiencing Laboratory Adverse Events (AEs) |
11; 13 | — |
| SECONDARY Change in Viral Titer (Day 1 to Day 180) |
-3.9; -4.2; -11.4 | 0.735 |
| SECONDARY Number of Participants Reporting Hospitalization |
4; 7 | — |
| SECONDARY Number of Participants Reporting Protocol-Specified SAEs |
0; 2 | — |
| SECONDARY Number of Participants Experiencing Unsolicited Non-Serious Adverse Events |
2; 0 | — |
| SECONDARY Time to First Negative Viral Load |
NA; NA; NA; 22 | 0.873 |
Summary
This is a phase 2 multi-center, double-blind, placebo-controlled study of the efficacy and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant recipients with symptomatic diarrhea due to Norovirus. The study involves a total of 160 Hematopoietic Stem Cell or Solid Organ transplant recipients, equal to or greater than 12 years of age with diagnosis of Norovirus who will be selected and randomly assigned (1:1) to nitazoxanide or placebo group. The study duration is 60 months and subject participation duration is 6 months. Given the safety of prolonged therapy with nitazoxanide, lack of interactions with common post-transplant medications, putative antiviral activity and prolonged duration of viral shedding we are assessing 56 doses of therapy. The longitudinal monitoring phase will provide useful information on the course of host and viral responses in subjects with chronic Norovirus infection with and without treatment. Randomization will be stratified by age group (pediatric (12 through 17 years) vs. adult (greater than or equal to 18 years)), chronicity of Norovirus-associated symptoms (acute (less than 14 days) vs. chronic (greater than or equal to 14 days)) and transplant type (solid organ (SOT)) vs. hematopoietic stem cell transplant (HSCT)). Enrolled subjects will participate in 2 phases of the study: Treatment Phase, which will include dosing with the assigned study agent for 28 days. Longitudinal Monitoring Phase which will include telephone call on Days 35, 53, 113, 173. Primary objective is 1) to assess the clinical efficacy of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients.
Eligibility Criteria
Inclusion Criteria
Subjects should meet all of the following inclusion criteria:
- Male or female age > / = 12 years.
- Recipient of a solid organ or hematopoietic stem cell transplant.
- Positive test result for Norovirus within 14 days of enrollment that is obtained as part of routine clinical care using a Norovirus testing available to the site.
- Active GI symptoms (diarrhea, or vomiting) that, in the opinion of the PI, are secondary to Norovirus. Patients must have active diarrhea, which is defined as at least 3 days of Bristol 6 or 7 stools in the past 2 weeks prior to enrollment per patient report.
- Willing and able to provide written informed consent and assent before initiation of any study procedures, consistent with local IRB policy.
- Subjects must be of non-childbearing potential or if of childbearing potential, must be using an effective method of birth control or must be abstinent.
- Non-childbearing potential is defined as surgically sterile or postmenopausal for > one year.
- Effective methods of birth control include the use of hormonal or barrier birth control such as implants, injectable contraceptives, combined oral contraceptives, intrauterine devices (IUDs),or condoms with spermicidal agents during study period. Female subjects must be using an effective method of birth control or practice abstinence and must agree to continue such precautions during the study and for 30 days after the Day 28 study visit.
- A woman is eligible if she is monogamous with a vasectomized male.This subject is considered low risk and not required to use contraception.
- Agrees to complete all screening requirements, study visits and procedures.
Exclusion Criteria
Subjects meeting any of the exclusion criteria at baseline will be excluded from study participation:
- Other identified infectious causes of diarrhea at screening. Alternative diagnosis requiring treatment would be considered a co-infection; if the testing is positive for a pathogen that the PI does not feel is causing the symptoms, they may be included but the PI or his/her designee must document that the positive test is not clinically significant, does not require treatment and is not causing the symptoms making the patient eligible for enrollment.
- Any condition that would, in opinion of the Site Investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
- Subjects receiving oral or intravenous immunoglobulin therapy concurrently or in the 14 days prior to enrollment.
- Nitazoxanide use for any illness in the previous 30 days prior to randomization.
- Have received experimental products within 30 days prior to the study entry or plan to receive experimental products at any time during the study
- Known sensitivity to nitazoxanide or any of the excipients comprising the nitazoxanide tablets.
- Subjects unable to swallow oral medications.
- Subjects with ostomy.
- Women who are pregnant or lactating or have a positive urine pregnancy test at screening/enrollment/Day 1.
Data sourced from ClinicalTrials.gov (NCT03395405). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.